brochure - global precision medicine market – estimate and forecast through (2015–2022)

Global Precision Medicine Market: Focus On Ecosystem, Sub-markets, Therapeutics

Application, & Regions – Estimate and Forecast Through (2015–2022)

The completion of first human genome project in 1990s has created the platform for the

development of precision medicine. Since, the precision medicine market was introduced in

early 21st century; the market has shown a promising growth.

Among different Precision Medicine ecosystem players, Diagnostic Tool segment is holding

the maximum market share and is expected to grow at XX% CAGR from 2015 to 2022.

BIS RESEARCH 2015

www.bisresearch.com ©2015|BIS

Analysis & Forecast:

Base Year: 2014

8 Year Annual Estimated Forecast

(2015-2022) Emphasis on Legal and

Regulatory

Framework Market, By Ecosystem:

Pharmaceuticals And Biotechnology

Companies, Diagnostic Companies,

Healthcare It Specialists/ Big Data

Companies, & Clinical Laboratories

Market, Sub-markets:

Companion Diagnostics, Biomarker-Based

Test, Targeted Therapeutics,

Pharmacogenomics (Pgx), Molecular

Diagnostics and Others

Market By Therapeutics:

Cancer/Oncology, Cardiovascular Disease

(CVD), Central Nervous System, Infectious

Diseases, and Others

Market, By Geography:

The Americas, Europe, Asia-Pacific and

Rest of the World

XX

XX

XX

XX

XX

XX

XX

2014 2015 2016 2017 2018 2019 2020 2021 2022

Pharma & Biotech Companies Diagnostic tool companies

Healthcare IT/ Big data companies Clinical laboratories

Ÿ What are the major market drivers, challenges and opportunities of the precision medicine market and their use cases?

Ÿ What are the precision medicine market trends and key developments for different precision medicine systems?

Ÿ What are the key developmental strategies in different applications across all regions?

Ÿ What are different types of precision medicine solutions and the latest precision medicine technologies?

Ÿ How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch

among others?

Ÿ Which geographical region will lead the global precision medicine market by the end of the forecast period?

Ÿ Who are the key players in the precision medicine market?

Ÿ What are the government regulations for different precision medicine solutions?

Ÿ What are different types of sub-markets in precision medicine market and what are the applications in which they are being used?

Ÿ What is the different used case scenarios considered under different applications?

Ÿ What are the different therapeutic applications in which precision medicine products are being used?

Ÿ What are the precision medicine market trends and key developments in different geographical regions?

The answers to the following key questions can be found in the report:


Table of Contents

1 REPORT SCOPE 4.3.1 POTENTIAL THREAT TO PERSONAL DATA

1.1 SCOPE OF THE STUDY 4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER

1.2 PRECISION MEDICINE: REPORT COVERAGE 4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE1.3 BIS RESEARCH METHODOLOGY

4.3.4 STRINGENT REGULATIONS AND STANDARDS1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY 4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE

APPLICATIONS OF PRECISION MEDICINE1.3.1.1 Geographical Analysis4.3.6 REIMBURSEMENT POLICIES AND 1.3.1.2 Demand Side & Supply Side Analysis

REGULATORY FRAMEWORK1.3.1.3 Data Synthesis and Bridging4.3.7 LIMITED KNOWLEDGE ABOUT THE 1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH

APPLICATION OF TEST AND TECHNIQUESMETHODOLOGY4.3.8 LACK OF RESEARCH AND EVIDENCES 1.3.3 KEY DATA POINT SOURCES

CREATING HINDRANCES IN ITS APPLICATION1.3.3.1 Data Points taken from Secondary Sources

4.4 MARKET OPPORTUNITIES1.3.3.2 Data Points taken from Primary Sources

4.4.1 INTRODUCTION OF PRECISION MEDICINE 1.4 REPORT DESCRIPTION SOLUTIONS IN DEVELOPING ECONOMIES

4.4.2 DOWNSIZING THE COST OF GENOME 2 EXECUTIVE SUMMARY SEQUENCING TO THREE DIGITS

3 MARKET OVERVIEW 5 INDUSTRY DYNAMICS3.1 INTRODUCTION 5.1 VALUE CHAIN ANALYSIS3.2 MARKET TIMELINE 5.1.1 DEVICE MANUFACTURER & DRUG 3.3 KEY PARTICIPANTS, STRATEGIES & PRODUCERS

DEVELOPMENTS 5.1.2 HEALTHCARE PROVIDERS3.3.1 GOVERNMENT AGENCIES 5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES3.3.2 ACADEMIC INSTITUTIONS 5.1.4 REGULATORS3.3.3 DEVICE & SERVICE PROVIDERS 5.1.5 THIRD PARTY PAYERS3.4 KEY MARKET STRATEGIES AND 5.1.6 PATIENTS

DEVELOPMENTS 5.2 PORTER FIVE FORCE ANALYSIS3.4.1 INTRODUCTION 5.2.1 BARGAINING POWER OF BUYER (PATIENT)3.4.2 PARTNERSHIPS, AGREEMENTS, AND 5.2.2 BARGAINING POWER OF SUPPLIER

COLLABORATIONS5.2.3 THREAT FROM SUBSTITUTE

3.4.3 MERGERS & ACQUISITIONS5.2.4 THREAT FROM A NEW ENTRANT

3.4.4 PRODUCT DEVELOPMENT AND LAUNCH5.2.5 INTENSITY OF COMPETITIVE RIVALRY

3.4.5 BUSINESS EXPANSION/CONTRACTS

3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS6 CONSORTIUMS, CERTIFICATION,

3.4.7 OTHERS (EVENTS & RECOGNITIONS) REGULATIONS, AND STANDARDS

6.1 INTRODUCTION4 MARKET DYNAMICS 6.1.1 REGULATORY BODIES4.1 INTRODUCTION 6.1.1.1 Food and Drug Administration (FDA)4.2 MARKET DRIVERS 6.1.1.2 Medicines and Healthcare products Regulatory 4.2.1 PATIENTS INVOLVEMENT IN PERSONAL Agency (MHRA)

HEALTHCARE 6.1.1.3 Therapeutic Goods Administration (TGA)-Australia4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. 6.1.1.4 Conformité Européenne (CE)

NEXT-GENERATION SEQUENCING 6.1.2 CONSORTIUMSTECHNOLOGIES, ULTRA-HIGH THROUGHPUT 6.1.3 ALLIANCES/ASSOCIATIONSSEQUENCING)

4.2.3 INCREASE IN GENETIC DISEASES7 GLOBAL PRECISION MEDICINE MARKET BY 4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES

ECOSYSTEM PLAYERS4.2.5 INTEGRATION OF BIG DATA HEALTHCARE 7.1 INTRODUCTIONCOMPANIES WITH PHARMA & BIOTECH

COMPANIES 7.1.1 MARKET STATISTICS

4.3 MARKET CHALLENGES 7.2 PHARMACEUTICALS AND BIOTECHNOLOGY




COMPANIES 9 GLOBAL PRECISION MEDICINE MARKET BY THERAPEUTICS7.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND

PARTICIPANTS 9.1 INTRODUCTION

7.2.1.1 Market Trends 9.1.1 MARKET STATISTICS

7.2.1.2 Market Developments 9.2 CANCER/ONCOLOGY

7.2.1.3 Key Participants 9.2.1 MARKET STATISTICS

7.3 DIAGNOSTIC COMPANIES 9.2.2 TYPES OF CANCER

7.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND 9.2.3 DRUGS & TESTSPARTICIPANTS 9.2.4 KEY MARKET TRENDS, DEVELOPMENTS &

7.3.1.1 Market Trends PARTICIPANTS

7.3.1.2 Market Developments 9.2.4.1 Market Trends

7.3.1.3 Key Participants 9.2.4.2 Market Developments

7.4 HEALTHCARE IT SPECIALISTS/ BIG DATA 9.2.4.3 Key ParticipantsCOMPANIES 9.3 CARDIOVASCULAR DISEASE (CVD)

7.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND 9.3.1 MARKET STATISTICSPARTICIPANTS 9.3.2 DRUGS & TESTS

7.4.1.1 Market Trends 9.3.3 MARKET TRENDS & MARKET DEVELOPMENTS7.4.1.2 Market Developments 9.3.3.1 Market trend7.4.1.3 Key Participants 9.3.3.2 Market Developments7.5 CLINICAL LABORATORIES 9.3.3.3 Key Participants7.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND 9.4 CENTRAL NERVOUS SYSTEM

PARTICIPANTS9.4.1 MARKET STATISTICS

7.5.1.1 Regulatory bodies and compliances9.4.2 NEUROLOGICAL

7.5.1.2 Market Trends9.4.2.1 Neurological Drugs & Tests

7.5.1.3 Key Participants9.4.3 PSYCHIATRIC DISORDERS

9.4.3.1 Psychiatric Disorder Drugs & Tests8 GLOBAL PRECISION MEDICINE MARKET BY

9.4.4 MARKET TENDS & MARKET DEVELOPMENTSSUB-MARKETS9.4.4.1 Market Trends8.1 INTRODUCTION9.4.4.2 Key Developments8.1.1 MARKET STATISTICS9.4.4.3 Key Participants8.2 COMPANION DIAGNOSTICS9.5 INFECTIOUS DISEASES8.3 BIOMARKER-BASED TEST9.5.1 MARKET STATISTICS8.3.1 ROLE OF BIOBANKING INTO BIOMARKER9.5.2 INFECTIOUS DISEASES DRUGS & TESTS8.3.2 KEY PARTICIPANTS9.5.3 MARKET DEVELOPMENTS & PARTICIPANTS8.4 TARGETED THERAPEUTICS9.5.3.1 Key Developments8.4.1 KEY PARTICIPANTS9.5.3.2 Key Participants8.5 PHARMACOGENOMICS (PGX)9.6 OTHERS8.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND 9.6.1 MARKET STATISTICSPARTICIPANTS9.6.2 MARKET TRENDS, DEVELOPMENTS & 8.5.1.1 Market Trends

PARTICIPANTS8.5.1.2 Market Developments9.6.2.1 Market Trends8.5.1.3 Key Participants9.6.2.2 Key Developments8.6 MOLECULAR DIAGNOSTICS9.6.2.3 Key Participants8.7 OTHERS

8.7.1 NEXT-GENERATION SEQUENCING10 GLOBAL PRECISION MEDICINE MARKET BY 8.7.2 CONSUMER GENOMICS

GEOGRAPHY8.7.2.1 Key Participants

10.1 INTRODUCTION8.7.3 3D PRINTING

10.1.1 MARKET STATISTICS8.7.4 PROSTHETICS MARKET

10.2 THE AMERICAS8.7.5 HUMAN TISSUES MARKET

10.2.1 NORTH AMERICA

10.2.1.1 The U.S.




10.2.1.2 Canada 11.4 BIOMÉRIEUX SA

10.2.1.3 Others 11.4.1 OVERVIEW

10.2.1.4 Key Market Trends, Developments and Participants 11.4.2 FINANCIALS

10.2.1.5 Regulations and Compliances 11.4.2.1 Overall Financials

10.2.1.6 Market Trends 11.4.2.2 Financials By Region

10.2.1.7 Market Developments 11.4.2.3 Financials By Segment

10.2.1.8 Key Participants 11.4.3 KEY DEVELOPMENTS

10.2.2 SOUTH AMERICA 11.4.4 SWOT ANALYSIS

10.2.2.1 Key Market Trends, Developments and Participants 11.5 CEPHEID INC.

10.2.2.2 Regulations and Compliances 11.5.1 OVERVIEW

10.2.2.3 Market Trends 11.5.2 FINANCIALS

10.2.2.4 Key Participants 11.5.2.1 Overall Financials

10.3 EUROPE 11.5.2.2 NET REVENUE BY SEGMENT

10.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND 11.5.2.3 NET REVENUE BY REGIONPARTICIPANTS 11.5.3 KEY DEVELOPMENTS

10.3.1.1 Regulations and Compliances 11.5.4 SWOT ANALYSIS10.3.1.2 Market Developments 11.6 CETICS HEALTHCARE TECHNOLOGIES GMBH10.3.1.3 Key Participants 11.6.1 OVERVIEW10.4 ASIA-PACIFIC (APAC) 11.6.2 FINANCIALS10.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND 11.6.3 KEY DEVELOPMENTS

PARTICIPANTS 11.6.4 SWOT ANALYSIS10.4.1.1 Market Developments 11.7 GE HEALTHCARE10.4.1.2 Key Participants 11.7.1 OVERVIEW10.5 REST OF THE WORLD/MIDDE EAST & AFRICA 11.7.2 FINANCIALS

(MEA)11.7.2.1 Overall financials

10.5.1 AFRICA11.7.2.2 NET REVENUE BY SEGMENT

10.5.1.1 Middle East11.7.2.3 Financial Summary

10.5.2 KEY MARKET DEVELOPMENTS AND 11.7.3 KEY DEVELOPMENTSPARTICIPANTS11.8 GLAXOSMITHKLINE PLC (GSK)10.5.2.1 Market Developments11.8.1 OVERVIEW10.5.2.2 Key Participants11.8.2 FINANCIALS

11.8.2.1 Overall Financials11 COMPANY PROFILES11.8.2.2 Financials By Segment11.1 ABBOTT LABORATORIES11.8.2.3 Financials By Region11.1.1 OVERVIEW11.8.2.4 Financials By Therapeutics11.1.2 FINANCIALS11.9 INTOMICS A/S11.1.2.1 Overall Financials11.9.1 OVERVIEW11.1.2.2 Financials by Segment11.9.2 FINANCIALS11.1.2.3 Financials by Region11.9.3 KEY DEVELOPMENTS11.1.2.4 Key Developments11.9.4 SWOT ANALYSIS11.1.3 SWOT ANALYSIS11.10 JOHNSON & JOHNSON11.2 ALMAC GROUP, LTD.11.10.1 OVERVIEW11.2.1 OVERVIEW11.10.2 FINANCIALS11.2.2 FINANCIALS11.10.2.1 Overall Financials11.2.3 KEY DEVELOPMENTS11.10.2.2 Net Revenue By Segment11.2.4 SWOT ANALYSIS11.10.2.3 Net revenue by Region11.3 ASURAGEN, INC.11.10.3 KEY DEVELOPMENTS11.3.1 OVERVIEW11.11 LABORATORY CORPORATION OF AMERICA 11.3.2 FINANCIALS

HOLDINGS11.3.3 KEY DEVELOPMENTS

11.11.1 OVERVIEW11.3.4 SWOT ANALYSIS




11.11.2 FINANCIALS 11.19 SANOFI PHARMA

11.11.2.1 Overall Financials 11.19.1 OVERVIEW

11.11.2.2 Financials by Segment 11.19.2 FINANCIALS

11.11.3 KEY DEVELOPMENTS 11.19.2.1 Overall Financials

11.11.4 SWOT ANALYSIS 11.19.2.2 NET REVENUE BY SEGMENT

11.12 MEDTRONIC 11.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED

11.12.1 OVERVIEW 11.20.1 OVERVIEW

11.12.2 FINANCIALS 11.20.2 FINANCIALS

11.12.2.1 Overall Financials 11.20.2.1 Overall Financials

11.12.3 KEY DEVELOPMENTS 11.20.3 KEY DEVELOPMENTS

11.13 NOVARTIS 11.20.4 SWOT ANALYSIS

11.13.1 OVERVIEW 11.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.

11.13.2 FINANCIALS 11.21.1 OVERVIEW

11.13.2.1 Overall Financials 11.21.2 FINANCIALS

11.13.2.2 Financials By Region 11.21.2.1 Overall Financials

11.13.2.3 Financials By Segment 11.21.2.2 Net Revenue By Segment

11.14 PFIZER INC. 11.21.2.3 Net Revenue By Segment

11.14.1 OVERVIEW 11.21.3 KEY DEVELOPMENTS

11.14.2 FINANCIALS 11.21.4 SWOT ANALYSIS

11.14.2.1 Overall Financials 11.22 AB-BIOTICS SA

11.14.2.2 NET REVENUE BY SEGMENT 11.22.1 OVERVIEW

11.14.2.3 NET REVENUE BY REGION 11.23 CARIS LIFE SCIENCES

11.14.3 KEY DEVELOPMENTS 11.23.1 OVERVIEW

11.14.4 SWOT ANALYSIS 11.24 HEALTHCORE, INC.

11.15 QIAGEN 11.24.1 OVERVIEW

11.15.1 OVERVIEW 11.25 IBM

11.15.1.1 BIOBASE Gmbh (subsidiary) 11.25.1 OVERVIEW

11.15.1.1.1 Overview 11.26 INNVENTIS

11.15.2 FINANCIALS 11.26.1 OVERVIEW

11.15.2.1 Overall Financials 11.27 INTEL CORPORATION

11.15.3 KEY DEVELOPMENTS(BIOBASE) 11.27.1 OVERVIEW

11.16 QUEST DIAGNOSTICS INC 11.28 MOLECULAR HEALTH GMBH

11.16.1 OVERVIEW 11.28.1 OVERVIEW

11.16.2 FINANCIALS 11.29 PRECISION FOR MEDICINE

11.16.2.1 Overall Financials 11.29.1 OVERVIEW

11.16.2.2 NET REVENUE BY SEGMENT

11.16.3 KEY DEVELOPMENTS

11.16.4 SWOT ANALYSIS

11.17 RANDOX LABORATORIES LTD.

11.17.1 OVERVIEW

11.17.2 FINANCIALS



11.18 ROCHE HOLDING AG-BR

11.18.1 OVERVIEW

11.18.2 FINANCIALS

11.18.2.1 Overall Financials

11.18.2.2 NET REVENUE BY SEGMENT






List of Tables

TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET

TABLE 2 FACTORS IMPACTING THE BUYER’S BARGAINING POWER

TABLE 3 FACTORS IMPACTING THE SUPPLIER’S BARGAINING POWER

TABLE 4 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE

TABLE 5 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT

TABLE 6 REGULATORY BODIES IN PRECISION MEDICINE MARKET

TABLE 7 CONSORTIUMS IN PRECISION MEDICINE MARKET

TABLE 8 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET

TABLE 9 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)

TABLE 10 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 11 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)

TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)

TABLE 13 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 14 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)

TABLE 15 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)

TABLE 16 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2015)

TABLE 17 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 18 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)

TABLE 19 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-

2022 ($BILLION)

TABLE 20 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 21 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC

APPLICATION, 2014-2022 ($BILLION)

TABLE 22 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)

TABLE 23 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 24 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 25 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)

TABLE 26 BENEFITS OF COMPANION DIAGNOSTICS

TABLE 27 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 28 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)

TABLE 29 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES

TABLE 30 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)




TABLE 31 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)

TABLE 32 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

2014-2022 ($MILLION)

TABLE 33 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)

TABLE 34 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 35 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)

TABLE 36 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 37 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)

TABLE 38 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION)

TABLE 39 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022

($BILLION)

TABLE 40 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 41 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)

TABLE 42 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY

TABLE 43 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY

TABLE 44 KEY DEVELOPMENTS (2013-2015)

TABLE 45 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)

TABLE 46 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)

TABLE 47 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 48 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR

TABLE 49 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR

TABLE 50 KEY DEVELOPMENTS (2014-2015)

TABLE 51 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 52 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)

TABLE 53 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 54 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY

TABLE 55 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS

TABLE 56 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS

TABLE 57 PSYCHIATRIC DISORDERS: KEY DEVELOPMENTS (2014-2015)

TABLE 58 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 59 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)

TABLE 60 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 61 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES




TABLE 62 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 63 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)

TABLE 64 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 65 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES

TABLE 66 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES

TABLE 67 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)

TABLE 68 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)

TABLE 69 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)

TABLE 70 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-

2022 ($BILLION)

TABLE 71 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)

TABLE 72 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION)

TABLE 73 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)

TABLE 74 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION)

TABLE 75 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)

TABLE 76 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION)




FIGURE 1 PRECISION MEDICINE MARKET STUDY

FIGURE 2 BIS RESEARCH METHODOLOGY

FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL MARKET

FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY

FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2014-2022 ($BILLION)

FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2014 – 2022 (BILLION)

FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2014 – 2022 (BILLION)

FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2014 – 2022 ($BILLION)

FIGURE 9 TIMELINE OF PRECISION MEDICINE

FIGURE 10 PRECISION MEDICINE: BENEFITS

FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE

FIGURE 12 ELEMENTS OF PRECISION MEDICINE TECHNOLOGY

FIGURE 13 DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES

FIGURE 14 PRECISION MEDICINE : AREAS OF INTEREST

FIGURE 15 PRECISION MEDICINE: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2015)

FIGURE 16 PRECISION MEDICINE : MERGERS & ACQUISITIONS( 2015)

FIGURE 17 PRECISION MEDICINE : KEY PRODUCT LAUNCH & DEVELOPMENTS (2015)

FIGURE 18 PRECISION MEDICINE: KEY BUSINESS EXPANSIONS & CONTRACTS (2015)

FIGURE 19 PRECISION MEDICINE : KEY PATENTS/ APPROVALS ( 2015)

FIGURE 20 PRECISION MEDICINE: EVENTS & RECOGNITION (2015)

FIGURE 21 MARKET DRIVERS AND CHALLENGES

FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS

FIGURE 23 PRECISION MEDICINE MARKET CHALLENGES: IMPACT ANALYSIS

FIGURE 24 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS

FIGURE 25 DOWNSIZING COST OF GENOME SEQUENCING

FIGURE 26 FLOW CHART OF PRECISION MEDICINE

FIGURE 27 VALUE CHAIN ANALYSIS

FIGURE 28 PRECISION MEDICINE MARKET: PORTER FIVE FORCE ANALYSIS

FIGURE 29 FACTORS IMPACTING THE DEGREE OF COMPETITION

FIGURE 30 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS

FIGURE 31 ROLE OF FDA IN PRECISION MEDICINE

FIGURE 32 CLASSIFICATION OF MEDICAL DEVICES

FIGURE 33 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS

FIGURE 34 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES

FIGURE 35 CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES

FIGURE 36 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES(2015)

FIGURE 37 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS

FIGURE 38 CHALLENGES FACED BY DIAGNOSTIC COMPANIES

FIGURE 39 BENEFITS OF BIG DATA

FIGURE 40 TRANSFORMATION OF MEDICINE

FIGURE 41 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE

FIGURE 42 CHALLENGES FACED BY BIG DATA COMPANIES

FIGURE 43 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2015)

FIGURE 44 OECD RECOMMENDATIONS ON THE GOVERNANCE OF CLINICAL TRIALS

FIGURE 45 TYPES OF PRECISION MEDICINE SUB-MARKET

List of Figures




FIGURE 46 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES

FIGURE 47 FUNCTION OF BIOMARKERS

FIGURE 48 LIST OF BIOBANKS

FIGURE 49 BIOBANKS SERVICES

FIGURE 50 DEVELOPMENT IN PGX

FIGURE 51 MODEL SYSTEMS USED IN PGX

FIGURE 52 CHALLENGES OF PGX STUDIES

FIGURE 53 FIGURE TITLE MISSING

FIGURE 54 MOLECULAR DIAGNOSTICS: APPLICATION

FIGURE 55 MOLECULAR DIAGNOSTICS: BENEFITS

FIGURE 56 GLOBAL PRECISION MEDICINE MARKET: BY THERAPEUTICS

FIGURE 57 TARGET SCOPE OF PRECISION MEDICINE BY CANCER TYPES

FIGURE 58 GLOBAL PRECISION MEDICINE MARKET CLASSIFICATION, BY GEOGRAPHY

FIGURE 59 KEY DRIVERS FOR PRECISION MEDICINE: NORTH AMERICA

FIGURE 60 OBJECTIVES OF THE PRECISION MEDICINE INITIATIVE

FIGURE 61 APAC: MARKET CHALLENGES

FIGURE 62 ABBOTT: OVERALL FINANCIALS ($BILLION), 2012-2014

FIGURE 63 ABBOTT: NET REVENUE BY SEGMENTS ($BILLION), 2012-2014

FIGURE 64 ABBOTT: NET REVENUE BY REGION, 2012-2014 ($BILLION)

FIGURE 65 ABBOTT: SWOT ANALYSIS

FIGURE 66 ALMAC: SWOT ANALYSIS

FIGURE 67 ASURAGEN: SWOT ANALYSIS

FIGURE 68 BIOMERIEUX: OVERALL FINANCIALS ($MILLION), 2012-2014

FIGURE 69 BIOMERIEUX: NET REVENUE BY REGION, 2014

FIGURE 70 BIOMERIEUX: NET REVENUE BY SEGMENT, 2014

FIGURE 71 BIOMERIEUX: SWOT ANALYSIS

FIGURE 72 CEPHEID: OVERALL FINANCIALS, 2012-2014 ($MILLION)

FIGURE 73 CEPHEID: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION)

FIGURE 74 CEPHEID: NET REVENUE, BY REGION, 2012-2014 ($MILLION)

FIGURE 75 CEPHEID: SWOT ANALYSIS

FIGURE 76 GE CORPORATION: OVERALL FINANCIALS, 2012-2014 ($BILLION)

FIGURE 77 GE CORPORATION: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION)

FIGURE 78 GSK: OVERALL FINANCIALS, 2012-2014 ($BILLION)

FIGURE 79 GSK: NET REVENUE BY SEGMENT, 2014 ($BILLION)

FIGURE 80 GSK: NET REVENUE BY REGION, 2014 ($BILLION)

FIGURE 81 GSK: NET REVENUE BY THERAPEUTICS, 2014 ($BILLION)

FIGURE 82 J&J: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)

FIGURE 83 J&J: NET REVENUE BY SEGMENT, 2012 - 2014 ($MILLION)

FIGURE 84 J&J: NET REVENUE BY REGION, 2012 - 2014 ($MILLION)

FIGURE 85 LABCORP: OVERALL FINANCIALS ($MILLION), 2012-2014

FIGURE 86 NET REVENUE BY SEGMENTS, 2012-2014($MILLION)

FIGURE 87 LABCORP: SWOT ANALYSIS

FIGURE 88 MEDTRONIC: OVERALL FINANCIALS, 2012 - 2014 ($MILLION)

FIGURE 89 NOVARTIS: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)

FIGURE 90 NOVARTIS: NET REVENUE BY REGION, 2014 ($BILLION)




FIGURE 91 NOVARTIS: NET REVENUE BY SEGMENT, 2014 ($BILLION)

FIGURE 92 PFIZER: OVERALL FINANCIALS, 2012 – 2014 ($BILLION)

FIGURE 93 PFIZER: NET REVENUE, BY SEGMENT, 2012-2014 ($MILLION)

FIGURE 94 PFIZER: NET REVENUE, BY REGION, 2012-2014 ($BILLION)

FIGURE 95 PFIZER : SWOT ANALYSIS

FIGURE 96 QIAGEN: OVERALL FINANCIALS ($MILLION), 2012-2014

FIGURE 97 QIAGEN: NET REVENUE BY REGION ($MILLION), 2014

FIGURE 98 QIAGEN: NET REVENUE BY SEGMENT, 2014

FIGURE 99 QUEST: OVERALL FINANCIALS, 2012 - 2014 ($MILLION)

FIGURE 100 QUEST: NET REVENUE, BY SEGMENT, 2012 - 2014 ($MILLION)

FIGURE 101 QUEST: SWOT ANALYSIS

FIGURE 102 ROCHE: OVERALL FINANCIALS, 2012-2014 ($BILLION)

FIGURE 103 ROCHE: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILLION)

FIGURE 104 ROCHE: SWOT ANALYSIS

FIGURE 105 SANOFI PHARMA: OVERALL FINANCIALS, 2012-2014($BILLION)

FIGURE 106 SANOFI PHARMA: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILION)

FIGURE 107 TAKEDA: OVERALL FINANCIALS, 2012-2014 ($BILLION)

FIGURE 108 TAKEDA: SWOT ANALYSIS

FIGURE 109 TEVA: OVERALL FINANCIALS, 2012 – 2014 ($BILLION)

FIGURE 110 TEVA: NET REVENUE SHARE, BY SEGMENT (2014)

FIGURE 111 TEVA: NET REVENUE SHARE, BY REGION (2014)

FIGURE 112 TEVA: SWOT ANALYSIS




About BIS (www.bisresearch.com)

BIS Research provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for

the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not

be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express

written consent of BIS Research. Customer will not disclose the contents of the report, whether directly in any media or indirectly through

incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other

information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings.

Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation

contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a

number of estimates and assumptions that, while considered reasonable by BIS Research as of the date of such statements, are

inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies

BIS Research

9100 West Bloomington Freeway,

Suite 159 Bloomington,

MN 55431

E-mail : [email protected]

Call Us : +1-650-228-0182

Global Delivery Center

A-21, Kailash Colony,

New Delhi,

India

Tel : +91 11 46120391

For more details regarding permission, please contact us:



brochure - global precision medicine market – estimate and forecast through (2015–2022)

Documents